Inhibikase Therapeutics, Inc. 8K

Inhibikase Therapeutics sold $50 million of common stock via its ATM facility to RA Capital Management to support completion of its Phase 3 PAH trial.

On July 14, 2026, Inhibikase Therapeutics, Inc. announced that it sold 25,000,000 shares of its common stock to RA Capital Management through its existing at-the-market (ATM) facility, raising gross proceeds of $50 million under its effective Form S-3 shelf registration and related ATM prospectus supplement; the company stated that, together with current cash and assuming full exercise of outstanding Series A and B warrants, this additional capital is expected to fund operations through the topline data readout for Part B of its ongoing global Phase 3 IMPROVE-PAH clinical trial of lead candidate IKT-001 for pulmonary arterial hypertension.

Filing Facts

CIK

1750149

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-302580

Alert Tier

7